Sicart Associates LLC Fibrogen Inc Transaction History

Sicart Associates LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 Apr 22, 2020	SELL	$23.3 - $45.96 $257,977 - $508,869	-11,072 Closed	0 $0
Q4 2019 Jan 30, 2020	SELL	$34.58 - $48.06 $518,700 - $720,900	-15,000 Reduced 57.53%	11,072 $475,000
Q2 2018 Jul 19, 2018	SELL	$44.9 - $64.95 $224,500 - $324,750	-5,000 Reduced 16.09%	26,072 $1.63 Million
Q4 2017 Jan 17, 2018	SELL	$41.95 - $60.1 $1.3 Million - $1.87 Million	-31,072 Closed	0 $0
Q3 2017 Nov 06, 2017	BUY	$33.4 - $53.9 $1.04 Million - $1.67 Million	31,072	31,072 $1.67 Million

47.1M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $32.8M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Sicart Associates LLC, based on Form 13F filings with the SEC.

Stay updated on Sicart Associates LLC with notifications on news.